Welcome to our dedicated page for Aurora Cannabis Common Shares news (Ticker: ACB), a resource for investors and traders seeking the latest updates and insights on Aurora Cannabis Common Shares stock.
Aurora Cannabis Inc. (NASDAQ: ACB, TSX: ACB) is a prominent Canadian company headquartered in Edmonton, Alberta, dedicated to the cultivation, production, and sale of high-quality cannabis for both medical and recreational use. The company's state-of-the-art facilities in Alberta embody advanced cultivation techniques that ensure the highest standards of quality, reliability, and safety in their products. Aurora's comprehensive portfolio includes renowned brands like Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, catering to a wide range of consumer preferences.
Aurora's operations extend beyond Canada, with significant international presence through medical cannabis exporting agreements. A notable subsidiary, Australis Capital Inc., plays a crucial role in participating in the U.S. cannabis market. The company's commitment to quality is further highlighted by its EU-GMP and TGA-GMP certified production facilities, ensuring compliance with rigorous international standards.
In recent developments, Aurora has launched three new cannabis-infused beverages targeted initially at veteran patients. These products, featuring innovative SōRSE® emulsion technology, offer an alternative form of cannabis consumption without the strong cannabis aroma or taste. Available in flavors like Neon Rush, Strawberry Pineapple Tropical Fizz, and Pineapple Coconut Fizz, these beverages are designed to enhance patient wellbeing with a refreshing and potent experience.
Financially, Aurora has achieved significant milestones, including the repayment of nearly $465 million in convertible debt and forecasting positive free cash flow for calendar 2024. The company has also strengthened its global footprint by acquiring MedReleaf Australia's majority equity, further solidifying its position in the Australian market. Aurora’s commitment to financial discipline and strategic expansions underscores its potential for sustainable growth.
Aurora's dedication to innovation and patient care is exemplified through its continuous development of new products and partnerships. Their recent launches include resin cartridges and pastilles in Australia, expanding their product range and enhancing patient access to premium medical cannabis. Additionally, the company's strategic moves in Europe, particularly in Germany, position it as a leader in the evolving cannabis landscape.
With a robust pipeline of products and strategic market expansions, Aurora Cannabis Inc. continues to pave the way for significant advancements in the global cannabis industry, committed to improving lives through high-quality, innovative cannabis products.
Aurora Cannabis (NASDAQ: ACB) announced its FY2024 results, highlighting a record annual adjusted EBITDA of $12.8 million and a 21% increase in total net revenue compared to the previous fiscal year. In Q4 2024, the company achieved its sixth consecutive quarter of positive adjusted EBITDA, with total net revenue up 5% YoY to $67.4 million, driven by a 20% YoY growth in global medical cannabis revenue to $45.6 million. Aurora finished the fiscal year with approximately $180 million in cash and no cannabis-related debt. The company reaffirms its goal of achieving positive free cash flow by the end of 2024.
Aurora Cannabis (NASDAQ: ACB) (TSX: ACB), a leading global medical cannabis company based in Canada, announced that it will host a conference call to discuss its fourth quarter and fiscal year 2024 results. The call is scheduled for Thursday, June 20, 2024, at 8:00 a.m. Eastern Time. The financial results for the quarter will be released before the market opens on the same day. Miguel Martin, CEO, and Simona King, CFO, will lead the call and a subsequent Q&A session. The webcast link can be accessed on the company's investor information page.
Aurora Cannabis, a leading medical cannabis company, has announced the launch of its premium 1.2g resin cartridges in Australia in partnership with MedReleaf Australia. These new products are now available for doctors to prescribe and are manufactured in Aurora's EU-GMP and TGA-GMP certified facilities.
The resin cartridges come under the Aurora and IndiMed brands, offering high-quality, full-spectrum options like Sourdough and Electric Honeydew. The products are designed to ensure exceptional flavor, potency, safety, and ease of use.
This move marks a significant expansion for Aurora, aiming to enhance patient access to premium cannabis in the Australian market.
Aurora Cannabis (NASDAQ: ACB; TSX: ACB) has appointed Rajesh Uttamchandani to its Board of Directors, effective May 15, 2024. Uttamchandani brings expertise in strategy development, innovation, human capital, and governance, with a background in senior roles at leading firms in technology, FinTech, and education sectors. His recent role was Chief People Officer at ApplyBoard, one of Canada's fastest-growing tech companies. Aurora's Chairman, Ron Funk, highlighted that Uttamchandani's experience aligns well with the company's strategic goals. Uttamchandani has served on boards of various organizations, including LifeSpeak and Ontario Cannabis Stores, and holds multiple advanced degrees and professional designations.
Aurora Cannabis Inc. marks the first shipment of medical cannabis products to the New Zealand market, showcasing premium, carefully crafted offerings. The company aims to redefine patient care by providing high-quality, potent products tailored to address various patient needs. The launch of these products signifies a significant milestone in improving medical cannabis accessibility in an emerging market like New Zealand.
Aurora Cannabis Inc. (ACB) and MedReleaf Australia have expanded their product offerings in Australia by introducing a new line of premium dried cannabis flower products. These products, including proprietary cultivars like Black Jelly, Chemango Kush, and Moon Berry, aim to provide patients with more choice and high-quality medical cannabis solutions. The expansion also includes the relaunch of the Vespera cultivar under the Aurora brand. The products are distributed by MedReleaf Australia, positioning itself as a leading distributor in the Australian market.
FAQ
What is the current stock price of Aurora Cannabis Common Shares (ACB)?
What is the market cap of Aurora Cannabis Common Shares (ACB)?
What is Aurora Cannabis Inc. primarily known for?
Where is Aurora Cannabis Inc. headquartered?
What are some of the brands under Aurora Cannabis?
What recent products has Aurora Cannabis launched?
What is Aurora's financial outlook for 2024?
What significant acquisitions has Aurora made recently?
What certifications do Aurora's production facilities hold?
How does Aurora contribute to the U.S. cannabis market?
What international operations does Aurora have?
How does Aurora ensure the quality of its products?
